BRUCE PAUL RANDAZZO, MD
Dermatology at Hampton Rd, Meadowbrook, PA
License number
Pennsylvania MD 047054-L
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
1428 Hampton Rd, Meadowbrook, PA 19046
Phone
(484) 865-5502
Personal information
See more information about BRUCE PAUL RANDAZZO at radaris.comName
Address
Phone
1428 Hampton Rd, Jenkintown, PA 19046
1428 Hampton Rd, Jenkintown, PA 19046
Professional information
Combination Therapy For Type Ii Diabetes Or Syndrome X
US Patent:
2004016, Aug 26, 2004
Filed:
Mar 1, 2004
Appl. No.:
10/790444
Inventors:
John Gwynne - Doylestown PA, US
Philippe Vitou - Paris, FR
Bruce Randazzo - Rydal PA, US
Philippe Vitou - Paris, FR
Bruce Randazzo - Rydal PA, US
Assignee:
Wyeth - Madison NJ
International Classification:
A61K031/4439, A61K031/405, A61K031/155
US Classification:
514/323000, 514/419000, 514/635000
Abstract:
This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.
Combination Therapy For Type Ii Diabetes Or Syndrome X
US Patent:
2003001, Jan 23, 2003
Filed:
Jun 6, 2002
Appl. No.:
10/163707
Inventors:
John Gwynne - Doylestown PA, US
Philippe Vitou - Paris, FR
Bruce Randazzo - Rydal PA, US
Philippe Vitou - Paris, FR
Bruce Randazzo - Rydal PA, US
Assignee:
Wyeth - Madison NJ
International Classification:
A61K031/5377, A61K031/4439, A61K031/405, A61K031/381, A61K031/343
US Classification:
514/232800, 514/339000, 514/337000, 514/415000, 514/443000, 514/444000, 514/469000
Abstract:
This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.